Imperial College London
Portrait Picture

DrLukeMoore

Faculty of Medicine, Department of Infectious Disease

Honorary Clinical Senior Lecturer
 
 
 
//

Contact

 

l.moore Website CV

 
 
//

Location

 

Chelsea and Westminster HospitalChelsea and Westminster Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Soriano:2021:10.1007/s40121-021-00507-6,
author = {Soriano, A and Carmeli, Y and Omrani, AS and Moore, LSP and Tawadrous, M and Irani, P},
doi = {10.1007/s40121-021-00507-6},
journal = {Infectious Diseases and Therapy},
pages = {1989--2034},
title = {Ceftazidime-avibactam for the treatment of serious gram-negative infections with limited treatment options: a systematic literature review},
url = {http://dx.doi.org/10.1007/s40121-021-00507-6},
volume = {10},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - IntroductionA systematic literature review was undertaken to evaluate real-world use of ceftazidime-avibactam for infections due to aerobic Gram-negative organisms in adults with limited treatment options.MethodsLiterature searches retrieved peer-reviewed publications and abstracts from major international infectious disease congresses from January 2015 to February 2021. Results were screened using pre-defined criteria to limit the dataset to relevant publications (notable exclusions were paediatric data and outcomes data for bacteria intrinsically resistant to ceftazidime-avibactam). Data for included publications were subjected to qualitative synthesis.ResultsSeventy-three relevant publications (62 peer-reviewed articles; 10 abstracts) comprising 1926 patients treated with ceftazidime-avibactam (either alone or combined with other antimicrobials) and 1114 comparator/control patients were identified. All patients were hospitalised for serious illness and most had multiple comorbidities. The most common infections were pneumonia, bacteraemia, and skin/soft tissue, urinary tract, or abdominal infections; smaller numbers of patients with meningitis, febrile neutropenia, osteomyelitis, and cystic fibrosis were also included. Carbapenem-resistant or carbapenemase-producing Enterobacterales (CRE; n = 1718) and carbapenem-resistant, multidrug-resistant (MDR), and extensively drug-resistant Pseudomonas aeruginosa (n = 150) were the most common pathogens. Most publications reported positive outcomes for ceftazidime-avibactam treatment (clinical success rates ranged from 45 to 100% and reported 30-day mortality from 0 to 63%), which were statistically superior versus comparators in some studies. ceftazidime-avibactam resistance emergence occurred infrequently and mostly in Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae strains.ConclusionThis review provides qualitative evidence of successful use of ceftazidime-avibactam for the
AU  - Soriano,A
AU  - Carmeli,Y
AU  - Omrani,AS
AU  - Moore,LSP
AU  - Tawadrous,M
AU  - Irani,P
DO  - 10.1007/s40121-021-00507-6
EP  - 2034
PY  - 2021///
SN  - 2193-8229
SP  - 1989
TI  - Ceftazidime-avibactam for the treatment of serious gram-negative infections with limited treatment options: a systematic literature review
T2  - Infectious Diseases and Therapy
UR  - http://dx.doi.org/10.1007/s40121-021-00507-6
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000684054900002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://link.springer.com/article/10.1007%2Fs40121-021-00507-6
UR  - http://hdl.handle.net/10044/1/91506
VL  - 10
ER  -
Download